What compounds target MAPK8?

BiohacksAI has identified 44 compounds that interact with MAPK8 (mitogen-activated protein kinase 8). Top compounds include: imatinib, sb 203580, alvocidib, foretinib, ruxolitinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MAPK8 (mitogen-activated protein kinase)?

MAPK8 is mitogen-activated protein kinase 8. It is a molecular target for 44 compounds documented in PubMed bioassay data. UniProt ID: P45983. NCBI Gene ID: 5599.

MAPK8

MOLECULAR TARGET

mitogen-activated protein kinase 8

UniProt: P45983 NCBI Gene: 559944 compounds

MAPK8 (mitogen-activated protein kinase 8) is targeted by 44 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAPK8

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	imatinib	5.47	236
2	sb 203580	4.92	136
3	alvocidib	4.52	91
4	foretinib	4.34	76
5	ruxolitinib	4.23	68
6	nilotinib	4.17	64
7	doramapimod	4.06	57
8	midostaurin	3.85	46
9	pazopanib	3.69	39
10	neratinib	3.66	38
11	abemaciclib	3.66	38
12	sb 202190	3.64	37
13	nintedanib	3.61	36
14	tryptanthrin	3.47	31
15	tae 684	3.43	30
16	fedratinib	3.40	29
17	gilteritinib	3.40	29
18	sp 600125	3.22	24
19	jnj 7706621	3.09	21
20	at 9283	3.09	21
21	lestaurtinib	3.04	20
22	pacritinib	3.04	20
23	sp600125	2.94	18
24	momelotinib	2.89	17
25	r 406	2.83	16
26	k 252a	2.83	16
27	azd 5438	2.71	14
28	kw 2449	2.64	13
29	ast 487	2.56	12
30	zotiraciclib	2.56	12
31	mk 5108	2.48	11
32	sgx 523	2.30	9
33	rebastinib	2.20	8
34	encorafenib	2.20	8
35	cyc 116	2.08	7
36	fostamatinib	2.08	7
37	zemirciclib	2.08	7
38	cep 32496	1.95	6
39	tanzisertib	1.95	6
40	Anisomycin	1.10	2
41	pictilisib	1.10	2
42	Axitinib	0.69	1
43	cardamonin	0.69	1
44	Hesperidin	0.69	1

About MAPK8 as a Drug Target

MAPK8 (mitogen-activated protein kinase 8) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 44 compounds with documented MAPK8 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAPK8 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.